Targeting specific receptors to reduce heart damage from cancer treatment
Official title: Dual targeting chemokine receptors prevents chemotherapy-induced cardiotoxicity
Funded at University of Louisville · NIH-11138735 · Data updated 2026-11-12
This study is looking at how certain proteins in the body can help protect your heart from damage caused by the chemotherapy drug doxorubicin, with the hope of finding better ways to keep your heart healthy while you’re being treated for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | August 1, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $681,996 |
| NIH project number | 5R01HL174922-02 |
| Project ID | NIH-11138735 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are receiving doxorubicin and are at risk of heart-related side effects.
✕Less likely to help
Patients who are not undergoing chemotherapy or those who do not have a history of heart issues may not benefit from this research.
What this research studies
This research investigates how targeting specific chemokine receptors can help prevent heart damage caused by the chemotherapy drug doxorubicin. The study focuses on the roles of SDF-1 and its receptors, CXCR4 and CXCR7, in promoting heart health and regeneration after chemotherapy. By understanding how these receptors interact, the research aims to develop new strategies to protect the heart during cancer treatment. Patients may benefit from improved heart function and reduced side effects from chemotherapy.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect the heart from damage caused by chemotherapy, improving the quality of life for cancer patients.
How similar studies have gone: Previous research has shown promise in using targeted receptor approaches for cardiac protection, indicating potential for success in this novel application.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Tan, Yi — University of Louisville
- Study coordinator: Tan, Yi
Related research
Other NIH-funded projects on the same topics.
-
Dual targeting of heart cell receptors to prevent chemotherapy heart damage
Atrial patients receiving the chemotherapy drug doxorubicin may be protected from heart damage by targeting two heart cell receptors at once.
-
Genetic clues for doxorubicin heart risk using patient-derived heart cells
A research project tests how human heart cells grown from stem cells react to a common chemotherapy to see which genetic differences may raise the risk of heart damage.
-
Targeting STK3 to protect the heart during breast cancer treatment
A new approach tests whether blocking STK3 can protect the heart from chemotherapy damage without reducing its cancer-fighting effect in breast cancer patients.
-
PET imaging to detect heart damage from chemotherapy
This research tests a new PET imaging tracer to detect early heart muscle damage in people who have received cancer chemotherapy.
-
PPAR-alpha and sex differences in chemotherapy-related heart injury
This project looks at why doxorubicin causes different heart side effects in men and women, and tests heart-protective ideas to help patients who need this chemotherapy.
-
Preventing heart damage from chemotherapy in older lymphoma patients
This study is looking to help older adults with lymphoma by finding ways to prevent heart damage from chemotherapy, figuring out who might be at risk, and understanding what patients and doctors prefer when it comes to treatment options.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.